Comparing Edgewise Therapeutics (NASDAQ:EWTX) & NovelStem International (OTCMKTS:NSTM)

Edgewise Therapeutics (NASDAQ:EWTX) and NovelStem International (OTCMKTS:NSTM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Earnings and Valuation

This table compares Edgewise Therapeutics and NovelStem International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79 million	($1.66)	-20.58
NovelStem International	$10,000.00	67.58	$2.38 million	$0.06	0.23

NovelStem International has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than NovelStem International, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Edgewise Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, NovelStem International has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500.

Profitability

This table compares Edgewise Therapeutics and NovelStem International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
NovelStem International	N/A	-124.84%	6,900.07%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Edgewise Therapeutics and NovelStem International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1	1	5	2	2.89
NovelStem International	0	0	0	0	0.00

Edgewise Therapeutics presently has a consensus target price of $39.67, suggesting a potential upside of 16.12%. Given Edgewise Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Edgewise Therapeutics is more favorable than NovelStem International.

Summary

NovelStem International beats Edgewise Therapeutics on 6 of the 11 factors compared between the two stocks.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

About NovelStem International

NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.